DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis Market by Type of Drug - Global Opportunity Analysis and Industry Forecast, 2017-2023" report has been added to ResearchAndMarkets.com's offering.
The global idiopathic pulmonary fibrosis market generated $1,616 million in 2016, and is projected to reach $3,569 million by 2023, registering a CAGR of 11.9% during the study period.
Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.
The global idiopathic pulmonary fibrosis market is segmented on the basis of type of drug and region. According to type of drug, the market is divided into pirfenidone and nintedanib. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
- MediciNova, Inc.
- Boehringer Ingelheim
- F. Hoffmann-La Roche
- FibroGen, Inc.
- Promedior, Inc.
- Merck & Co., Inc.
- Galapagos NV
- Bristol-Myers Squibb Company
- Prometic Life Sciences Inc.
- Cipla Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type
Chapter 5 Idiopathic Pulmonary Fibrosis Market, By Region
Chapter 6 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/4gg3r6/global_idiopathic?w=4